La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Zhejiang Wolwo Bio-Pharmaceutical Gestione

Gestione criteri di controllo 3/4

We currently do not have sufficient information about the CEO.

Informazioni chiave

Gengxi Hu

Amministratore delegato

CN¥780.0k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	13.6yrs
Proprietà del CEO	8.3%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Has Announced That Its Dividend Will Be Reduced To CN¥0.185

Jun 30

Investor Optimism Abounds Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) But Growth Is Lacking

May 27

Calculating The Fair Value Of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357)

May 07

Is Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) A Risky Investment?

Mar 22

AMMINISTRATORE DELEGATO

Gengxi Hu (60 yo)

13.6yrs

Mandato

CN¥780,000

Compensazione

Mr. Gengxi Hu serves as Consultant at Shanghai Creation Investment Management Co. Ltd. Mr. Hu has been Non-Independent Director at Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. since January 28, 2011 and ser...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Gengxi Hu	Chairman & GM	13.6yrs	CN¥780.00k	8.35% CN¥ 831.6m
Lu Zhang	Deputy GM & Non-Independent Director	7.6yrs	CN¥780.00k	Nessun dato
Ziqiang Bi	Deputy GM & Non-Independent Director	1.7yrs	CN¥780.00k	Nessun dato
Yanni Chen	Non-Independent Director	13.6yrs	Nessun dato	Nessun dato
Guoliang Xu	Independent Director	4.5yrs	CN¥120.00k	Nessun dato
Tao Jin	Chair of the Supervisory Board	7yrs	Nessun dato	Nessun dato
Huifeng Yang	Supervisor	7yrs	Nessun dato	Nessun dato
Feida Zhang	Independent Director	1.7yrs	CN¥120.00k	Nessun dato

7.0yrs

Durata media

52yo

Età media

Consiglio di amministrazione esperto: 300357's board of directors are considered experienced (7 years average tenure).

Zhejiang Wolwo Bio-Pharmaceutical Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Approves Executive Appointments

High number of new and inexperienced directors

Recent updates

Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Has Announced That Its Dividend Will Be Reduced To CN¥0.185

Dividend reduced to CN¥0.18

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Announces Final Cash Dividend (Tax Included) on (A Shares) for 2023, Payable on 04 July 2024

Now 20% undervalued after recent price drop

Investor Optimism Abounds Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) But Growth Is Lacking

Calculating The Fair Value Of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357)

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.14 in 1Q 2023)

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 19, 2024

Is Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) A Risky Investment?

New minor risk - Share price stability

Investor sentiment improves as stock rises 20%

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024

Third quarter 2023 earnings released: EPS: CN¥0.23 (vs CN¥0.28 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.17 in 2Q 2022)

Investor sentiment improves as stock rises 18%

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 6, 2023

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Approves the Cash Dividend for the Year 2022

First quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.17 in 1Q 2022)

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Approves Executive Appointments

Price target decreased to CN¥50.12

Third quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.24 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.15 in 2Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.15 in 2Q 2021)

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Implements Final Profit Distribution Plan A shares for 2021, Payable on June 16, 2022

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2021

Investor sentiment improved over the past week

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2021

High number of new and inexperienced directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.23 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.13 in 2Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.13 in 2Q 2020)

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Announces Final Cash Dividend for 2020, Payable on 01 June 2021

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Approves Final Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.079 in 1Q 2020)

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2020

New 90-day low: CN¥60.37

Full year 2020 earnings released: EPS CN¥0.53 (vs CN¥0.57 in FY 2019)

Revenue and earnings miss expectations

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 01, 2021

New 90-day high: CN¥89.40

New 90-day high: CN¥70.51

New 90-day high: CN¥63.10

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. announced that it expects to receive CNY 725 million in funding

Third quarter earnings released

New 90-day low: CN¥54.70

New 90-day low - CN¥57.51

Earnings released

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 20, 2020